1.Clinicopathological features and treatment of extremity bone metastasis in patients with endometrial carcinoma: a case report and review.
Guo-qing JIANG ; Yu-nong GAO ; Min GAO ; Hong ZHENG ; Xin YAN ; Wen WANG ; Na AN ; Kun CAO
Chinese Medical Journal 2011;124(4):622-626
Unlike other non-gynecologic solid tumors, such as breast cancer, lung cancer, metastasis to bone from endometrial carcinoma is rare, metastasis to extremity is extremely rare. We report a 51-year-old multiparous woman with FIGO Stage IVb Grade 2 endometrial adenocarcinoma which metastasized to left lower extremity bone. She received an amputation of left lower extremity below the knees, and a total abdominal hysterectomy and bilateral salpingo-oophorectomy, and followed by systemic chemotherapy, radiation therapy to the pelvis and progestational agent. She had a complete response to above treatments, and disease-free survival for 10 months. After recurrence, she received chemotherapy, radiotherapy and progestational agent once again. She had lived 56 months and is still alive by the time of report. Metastasis of endometrial carcinoma to extremity bone can rarely occur and should be considered when the patient with endometrial carcinoma complained of unexplained pain and swelling associated with extremity bone.
Bone Neoplasms
;
pathology
;
secondary
;
surgery
;
Endometrial Neoplasms
;
complications
;
pathology
;
surgery
;
Female
;
Humans
;
Middle Aged
3.Synchronous primary endometrial and fallopian tube cancers: one case report.
Huan WANG ; Song-shu XIAO ; Fei ZENG
Journal of Southern Medical University 2011;31(12):2093-2094
A patient was admitted for menopause for 2 years and abnormal vaginal bleeding and abdominal pain for 2 months. Gynecological examination revealed uterine atrophy without abnormal findings in the bilateral adnexa. CA125 and CEA levels were normal. The patient underwent laparoscopically assisted vaginal hysterectomy with bilateral salpingo-oophorectomy. Pathological examination of the surgical specimens revealed synchronous primary cancers stage Ia in both the endometrium and the right fallopian tube. The patient then received 6 cycles of chemotherapy with oxaliplatin combined with docetaxel given intravenously and remained alive without evidence of recurrence. Synchronous primary endometrial and fallopian tube cancer is a rare clinical entity, and laparoscopic surgery with postoperative chemotherapy can be considered for stage I patients.
Adenocarcinoma
;
pathology
;
surgery
;
Endometrial Neoplasms
;
pathology
;
surgery
;
Fallopian Tube Neoplasms
;
pathology
;
surgery
;
Female
;
Humans
;
Laparoscopy
;
Middle Aged
;
Neoplasms, Multiple Primary
;
pathology
;
surgery
4.The utility of the 3D imaging software in the macroscopic rendering of complex gynecologic specimens.
Luca RONCATI ; Beniamino PALMIERI ; Teresa PUSIOL ; Francesco PISCIOLI ; Michele SCIALPI ; Giuseppe BARBOLINI ; Antonio MAIORANA
Journal of Gynecologic Oncology 2015;26(2):168-169
No abstract available.
Abdomen/pathology/surgery
;
Adult
;
Endometrial Neoplasms/complications/*pathology/radiography/surgery
;
Endometriosis/complications/*pathology/radiography/surgery
;
Female
;
Humans
;
Image Enhancement/*methods
;
Imaging, Three-Dimensional/*methods
;
Pelvis/pathology/radiography/surgery
;
Radiography, Abdominal
;
Sarcoma, Endometrial Stromal/complications/*pathology/radiography/surgery
;
*Software
;
Specimen Handling
5.Clinicopathologic features and prognostic factors of endometrial stromal sarcoma: a study of 55 cases.
Jing-li SHI ; Ning-hai CHENG ; Li-na GUO ; Li-juan LIAN
Chinese Journal of Pathology 2011;40(8):517-522
OBJECTIVETo investigate the clinicopathologic features and the prognostic factors of endometrial stromal sarcoma (ESS).
METHODS55 cases of endometrial stromal sarcoma were reviewed and categorized into 3 pathologic types based on the related literatures, i.e., low grade endometrial stromal sarcoma (LGESS), undifferentiated endometrial sarcoma with nuclear uniformity (UES-U) and undifferentiated endometrial sarcoma with nuclear pleomorphism (UES-P). Meanwhile, the pathologic features were reviewed, including fibroid, myoid, mucoid, and epithelioid differentiation and mitotic index. Clinical and follow-up data were collected.
RESULTSIn endometrial stromal sarcoma, two or three pathologic types co-existed in one case, including 12.8% (5/39) of LGESS, 5/9 of UES-U, and 5/7 of UES-P. Mitotic index varied in different regions of one tumor from rare to high. Multi-differentiation was also commonly seen in ESS. The numbers of cases in LGESS, UES-U and UES-P were 39, 9 and 7, with recurrence rate of 51.6% (16/31), 5/6 and 2/3, respectively. There was no death case in LGESS, and 2 cases were died in UES-U and UES-P, respectively. In the 2 death cases of UES-U, both had focus of UES-P. There was a significant difference in the recurrence rate between cases with different mitotic index (≥ 10/10 HPF and < 10/10 HPF, P = 0.009), especially in LGESS group. All death cases had high mitotic index (> 30/10 HPF).
CONCLUSIONSIt is a common phenomenon in ESS that two or three pathologic types may exist in one case, especially in UES-U and UES-P. And multi-differentiation is also commonly seen in ESS. So adequate pathologic sampling is important for pathologists to make a correct diagnosis of ESS in daily work. The recurrence rates are significantly higher in cases with high mitotic index, especially in LGESS. In addition, the presence of UES-P and high mitotic index may increase the risk of death in the patients.
Adult ; Aged ; Aged, 80 and over ; Cell Differentiation ; Endometrial Neoplasms ; classification ; pathology ; surgery ; Endometrial Stromal Tumors ; pathology ; surgery ; Female ; Follow-Up Studies ; Humans ; Hysterectomy ; Middle Aged ; Mitotic Index ; Neoplasm Recurrence, Local ; Sarcoma, Endometrial Stromal ; classification ; pathology ; surgery ; Survival Rate ; Young Adult
6.Cotyledonoid hydropic intravenous leiomyomatosis of uterus: report of a case.
Ying WU ; Ju-fang CAI ; Guo-feng ZHANG ; Shou-xiang WENG ; Yi-jian YU
Chinese Journal of Pathology 2006;35(12):763-764
Adult
;
Diagnosis, Differential
;
Female
;
Humans
;
Hysterectomy
;
Leiomyomatosis
;
pathology
;
surgery
;
Sarcoma, Endometrial Stromal
;
pathology
;
Uterine Neoplasms
;
pathology
;
surgery
;
Uterus
;
blood supply
;
Vascular Neoplasms
;
pathology
;
surgery
7.Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report.
Bo Han NING ; Qing Xia ZHANG ; Hui YANG ; Ying DONG
Journal of Peking University(Health Sciences) 2023;55(2):366-369
Corded and hyalinized endometrioid carcinoma (CHEC) is a morphologic variant of endo-metrioid adenocarcinoma. The tumor exhibits a biphasic appearance with areas of traditional low-grade adenocarcinoma merging directly with areas of diffuse growth composed of epithelioid or spindled tumor cells forming cords, small clusters, or dispersed single cells. It is crucial to distinguish CHEC from its morphological mimics, such as malignant mixed mullerian tumor (MMMT), because CHECs are usually low stage, and are associated with a good post-hysterectomy prognosis in most cases while the latter portends a poor prognosis. The patient reported in this article was a 54-year-old woman who presented with postmenopausal vaginal bleeding for 2 months. The ultrasound image showed a thickened uneven echo endometrium of approximately 12.2 mm and a detectable blood flow signal. Magnetic resonance imaging revealed an abnormal endometrial signal, considered endometrial carcinoma (Stage Ⅰ B). On hysterectomy specimen, there was an exophytic mass in the uterine cavity with myometrium infiltrating. Microscopically, most component of the tumor was well to moderately differentiated endometrioid carcinoma. Some oval and spindle stromal cells proliferated on the superficial surface of the tumor with a bundle or sheet like growth pattern. In the endometrial curettage specimen, the proliferation of these stromal cells was more obvious, and some of the surrounding stroma was hyalinized and chondromyxoid, which made the stromal cells form a cord-like arrangement. Immunostains were done and both the endometrioid carcinoma and the proliferating stroma cells showed loss of expression of DNA mismatch repair protein MLH1/PMS2 and wild-type p53 protein. Molecular testing demonstrated that this patient had a microsatellite unstable (MSI) endometrial carcinoma. The patient was followed up for 6 months, and there was no recurrence. We diagnosed this case as CHEC, a variant of endometrioid carcinoma, although this case did not show specific β-catenin nuclear expression that was reported in previous researches. The striking low-grade biphasic appearance without TP53 mutation confirmed by immunohistochemistry and molecular testing supported the diagnosis of CHEC. This special morphology, which is usually distributed in the superficial part of the tumor, may result in differences between curettage and surgical specimens. Recent studies have documented an aggressive clinical course in a significant proportion of cases. More cases are needed to establish the clinical behaviors, pathologic features, and molecular profiles of CHECs. Recognition of the relevant characteristics is the prerequisite for pathologists to make correct diagnoses and acquire comprehensive interpretation.
Female
;
Humans
;
Middle Aged
;
Carcinoma, Endometrioid/surgery*
;
Endometrial Neoplasms/pathology*
;
Endometrium/metabolism*
;
Adenocarcinoma/pathology*
;
Stromal Cells/pathology*
8.Solitary spleen metastasis of endometrial carcinoma: a case report.
Chinese Journal of Cancer 2010;29(1):30-31
Adenocarcinoma
;
drug therapy
;
pathology
;
secondary
;
surgery
;
Chemotherapy, Adjuvant
;
Endometrial Neoplasms
;
drug therapy
;
pathology
;
surgery
;
Female
;
Humans
;
Hysterectomy
;
Middle Aged
;
Splenectomy
;
Splenic Neoplasms
;
drug therapy
;
pathology
;
secondary
;
surgery
10.Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles.
Wen Yu SHAO ; You Ting DONG ; Qiao Ying LYU ; Jiong Bo LIAO ; Yu XUE ; Xiao Jun CHEN
Chinese Journal of Obstetrics and Gynecology 2023;58(10):742-754
Objective: To investigate the impact of molecular classification and key oncogenes on the oncologic outcomes in patients with endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH) receiving fertility-preserving treatment. Methods: Patients with EC and AEH undergoing progestin-based fertility-preserving treatment and receiving molecular classification as well as key oncogenes test at Obstetrics and Gynecology Hospital, Fudan University from January 2021 to March 2023 were reviewed. Hysteroscopic lesion resection and endometrial biopsy were performed before initiating hormone therapy and every 3 months during the treatment to evaluate the efficacy. The risk factors which had impact on the treatment outcomes in EC and AEH patients were further analyzed. Results: Of the 171 patients analyzed, the median age was 32 years, including 86 patients with EC and 85 patients with AEH. The distribution of molecular classification was as follows: 157 cases (91.8%) were classified as having no specific molecular profile (NSMP); 9 cases (5.3%), mismatch repair deficient (MMR-d); 3 cases (1.8%), POLE-mutated; 2 cases (1.2%), p53 abnormal. No difference was found in the cumulative 40-week complete response (CR) rate between the patients having NSMP or MMR-d (61.6% vs 60.0%; P=0.593), while the patients having MMR-d had increased risk than those having NSMP to have recurrence after CR (50.0% vs 14.4%; P=0.005). Multi-variant analysis showed PTEN gene multi-loci mutation (HR=0.413, 95%CI: 0.259-0.658; P<0.001) and PIK3CA gene mutation (HR=0.499, 95%CI: 0.310-0.804; P=0.004) were associated with a lower cumulative 40-week CR rate, and progestin-insensitivity (HR=3.825, 95%CI: 1.570-9.317; P=0.003) and MMR-d (HR=9.014, 95%CI: 1.734-46.873; P=0.009) were independent risk factors of recurrence in EC and AEH patients. Conclusions: No difference in cumulative 40-week CR rate is found in the patients having NSMP or MMR-d who received progestin-based fertility-preserving treatment, where the use of hysteroscopy during the treatment might be the reason, while those having MMR-d have a higher risk of recurrence after CR. Oncogene mutation of PTEN or PIK3CA gene might be associated with a lower response to progestin treatment. The molecular profiles help predict the fertility-preserving treatment outcomes in EC and AEH patients.
Pregnancy
;
Female
;
Humans
;
Adult
;
Hyperplasia
;
Progestins
;
Fertility Preservation
;
Endometrial Neoplasms/pathology*
;
Endometrial Hyperplasia/surgery*
;
Treatment Outcome
;
Precancerous Conditions
;
Fertility
;
Class I Phosphatidylinositol 3-Kinases
;
Retrospective Studies